Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Toxicol Pathol ; 47(1): 82-92, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30585133

RESUMO

The 6-month Tg.rasH2 mouse carcinogenicity model provides an acceptable alternative to the 2-year carcinogenicity study in CD-1 mice. However, key questions related to the use of this model for testing antisense oligonucleotides (ASOs) include the similarity in the biologic response between mouse strains and the feasibility of using data from the CD-1 mouse to set doses and dose schedules for a Tg.rasH2 carcinogenicity study. To evaluate the potential strain differences, four distinct 2'- O-(2-methoxyethyl) ASOs were administered to CByB6F1 (wild type), Tg.rasH2 (hemizygous), and CD-1 mice. There were no meaningful differences in clinical signs, body weight, food consumption, or serum chemistry and hematology parameters. Histopathology evaluation indicated little to no difference in the spectrum or magnitude of changes present. The cytokine/chemokine response was also not appreciably different between the strains. This was consistent with the similarity in ASO concentration in the liver between the mouse strains tested. As the class effects of the ASOs were not meaningfully different between CD-1, CByB6F1, or Tg.rasH2 mice, data from nonclinical studies in CD-1 mice can be used for dose selection and expectation of effect in the Tg.rasH2 mouse.


Assuntos
Carcinógenos/toxicidade , Genes ras , Oligonucleotídeos Antissenso/toxicidade , Oligorribonucleotídeos/toxicidade , Testes de Toxicidade , Animais , Sequência de Bases , Carcinógenos/classificação , Carcinógenos/farmacocinética , Citocinas/sangue , Feminino , Hemizigoto , Masculino , Camundongos Endogâmicos ICR , Camundongos Transgênicos , Oligonucleotídeos Antissenso/classificação , Oligonucleotídeos Antissenso/farmacocinética , Oligorribonucleotídeos/classificação , Oligorribonucleotídeos/farmacocinética , Tamanho do Órgão/efeitos dos fármacos , Especificidade de Órgãos , Especificidade da Espécie , Fatores de Tempo , Distribuição Tecidual , Testes de Toxicidade/métodos , Testes de Toxicidade/normas
2.
Proc Natl Acad Sci U S A ; 105(10): 3921-6, 2008 Mar 11.
Artigo em Inglês | MEDLINE | ID: mdl-18322014

RESUMO

Thioredoxin-interacting protein (Txnip) inhibits thioredoxin NADPH-dependent reduction of protein disulfides. Total Txnip knockout (TKO) mice adapted inappropriately to prolonged fasting by shifting fuel dependence of skeletal muscle and heart from fat and ketone bodies to glucose. TKO mice exhibited increased Akt signaling, insulin sensitivity, and glycolysis in oxidative tissues (skeletal muscle and hearts) but not in lipogenic tissues (liver and adipose tissue). The selective activation of Akt in skeletal muscle and hearts was associated with impaired mitochondrial fuel oxidation and the accumulation of oxidized (inactive) PTEN, whose activity depends on reduction of two critical cysteine residues. Whereas muscle- and heart-specific Txnip knockout mice recapitulated the metabolic phenotype exhibited by TKO mice, liver-specific Txnip knockout mice were similar to WT mice. Embryonic fibroblasts derived from knockout mice also accumulated oxidized (inactive) PTEN and had elevated Akt phosphorylation. In addition, they had faster growth rates and increased dependence on anaerobic glycolysis due to impaired mitochondrial fuel oxidation, and they were resistant to doxorubicin-facilitated respiration-dependent apoptosis. In the absence of Txnip, oxidative inactivation of PTEN and subsequent activation of Akt attenuated mitochondrial respiration, resulting in the accumulation of NADH, a competitive inhibitor of thioredoxin NADPH-reductive activation of PTEN. These findings indicate that, in nonlipogenic tissues, Txnip is required to maintain sufficient thioredoxin NADPH activity to reductively reactivate oxidized PTEN and oppose Akt downstream signaling.


Assuntos
Proteínas de Transporte/metabolismo , Dissulfetos/metabolismo , PTEN Fosfo-Hidrolase/metabolismo , Transdução de Sinais , Tiorredoxinas/metabolismo , Animais , Dieta , Embrião de Mamíferos/citologia , Embrião de Mamíferos/efeitos dos fármacos , Fibroblastos/citologia , Fibroblastos/efeitos dos fármacos , Deleção de Genes , Glicólise/efeitos dos fármacos , Homeostase/efeitos dos fármacos , Insulina/farmacologia , Resistência à Insulina , Lipídeos/administração & dosagem , Lipídeos/sangue , Lipídeos/farmacologia , Camundongos , Camundongos Knockout , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Neoplasias/patologia , Especificidade de Órgãos/efeitos dos fármacos , Oxirredução/efeitos dos fármacos , Fenótipo , Fosfoproteínas/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Transdução de Sinais/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA